TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11934776

Group type: EXPERIMENTAL
Intervention: Questionnaire with multiple choice questions about terms of test accuracy and a clinical vignette with the results of a diagnostic test described in three different ways.
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Providing the scan's sensitivity and specificity
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Simple wording of the likelihood ratio
Number of subjects: 263
Study: 10778622

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no selegiline)
Number of subjects: 32
Study: 8580384

Group type: EXPERIMENTAL
Intervention: IL‐1 alpha (0.03 g/kg as a 30 minute infusion daily for 5 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IL‐2 (6 x 10(5) IU/kg every 8 hours for 5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: IL‐6 (5-day continuous infusion)
Number of subjects: 14
Study: 31904708

Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 0 years (same-age partner)
Number of subjects: 5351

Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 10 years older
Number of subjects: 5351

Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 15 years older
Number of subjects: 5351

Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 15 years older for AGYW ages 15-16 years
Number of subjects: 5351

Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 8-11 years older for AGYW ages 17-18 years
Number of subjects: 5351

Group type: EXPERIMENTAL
Intervention: Partners for AGYW ages 19-21 years
Number of subjects: 5351
Study: 31567579

Group type: EXPERIMENTAL
Intervention: Ketorolac with opioid medication
Number of subjects: 128

Group type: COMPARATOR
Intervention: Opioids alone (Control)
Number of subjects: 128
Study: 28513346

Group type: EXPERIMENTAL
Intervention: Psychoeducation and Problem Solving (PEPS) therapy
Number of subjects: 444

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 444
Study: 25677244

Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1000 ppm F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fluoride dentifrice (5000 ppm F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice (fluoride free)
Number of subjects: 0
Study: 23778325

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 21262886

Group type: EXPERIMENTAL
Intervention: Experimental protocol (automated ABR testing first, followed by OAE testing if ABR not passed)
Number of subjects: 2167

Group type: COMPARATOR
Intervention: Standard WIN protocol (OAE testing first, followed by automated ABR testing if OAE not passed)
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Experimental protocol
Number of subjects: 2167
Study: 19731968

Group type: EXPERIMENTAL
Intervention: Aripiprazole 20-30 mg/day
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Haloperidol 7-10 mg/day
Number of subjects: 1294
Study: 17324745

Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: amlodipine (5 mg)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25 mg)
Number of subjects: 208

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 208
Study: 15054155

Group type: EXPERIMENTAL
Intervention: Intra-articular triamcinolone hexacetonide with methotrexate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intra-articular triamcinolone hexacetonide without methotrexate (control)
Number of subjects: 38
Study: 11319656

Group type: EXPERIMENTAL
Intervention: Six meals (6vs2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Two meals (6vs2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Six meals (6+vs2+)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Two meals (6+vs2+)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Six meals (6+vsAMFAST)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Morning fast (6+vsAMFAST)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Meal frequency (6vs2, 6+vs2+, 6+vsAMFAST)
Number of subjects: 26
Study: 9713916

Group type: EXPERIMENTAL
Intervention: 3 x 10(6) U IFN alpha (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 x 10(6) U IFN gamma (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) U IFN alpha plus 1.5 x 10(6) U IFN gamma (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 x 10(6) U IFN alpha plus 1.5 x 10(6) U IFN gamma (Group D)
Number of subjects: 0
Study: 7979935

Group type: EXPERIMENTAL
Intervention: 20% benzocaine spray
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments (benzocaine and placebo)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical anesthetic (benzocaine)
Number of subjects: 16
Study: 2658886

Group type: EXPERIMENTAL
Intervention: Automated control of sodium nitroprusside administration
Number of subjects: 180

Group type: COMPARATOR
Intervention: Manual control of sodium nitroprusside administration
Number of subjects: 180
Study: 952694

Group type: EXPERIMENTAL
Intervention: Phenoperidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Halothane 0.5%
Number of subjects: 50
Study: 31819387

Group type: EXPERIMENTAL
Intervention: Resveratrol + Curcumin (500 mg each daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29088038

Group type: EXPERIMENTAL
Intervention: Continuous posterior lumbar plexus block (PNB)
Number of subjects: 159

Group type: COMPARATOR
Intervention: PAI with ropivacaine, ketorolac, and epinephrine (PAI-R)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: PAI with liposomal bupivacaine, ketorolac, and epinephrine (PAI-L)
Number of subjects: 159
Study: 26698120

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (12.9 mmoles nitrate)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted beetroot juice)
Number of subjects: 21
Study: 24026599

Group type: EXPERIMENTAL
Intervention: Individual financial incentives
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Practice-level financial incentives
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Combined financial incentives
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no incentives)
Number of subjects: 125
Study: 21460146

Group type: EXPERIMENTAL
Intervention: Group B (detailed instruction)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Group A (basic instruction)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Evaluation of abnormal profiles
Number of subjects: 10
Study: 18095965

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine (1 mg.kg(‐1) ketamine + 1.2 mg.kg(‐1) propofol)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Propofol-fentanyl (1 microg.kg(‐1) fentanyl + 1.2 mg.kg(‐1) propofol)
Number of subjects: 32
Study: 17153882

Group type: EXPERIMENTAL
Intervention: Soy formulas and rice formula
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Whey hydrolysates
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mixed hydrolysates and casein hydrolysates
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mixed hydrolysate 1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peptide weight of each formula
Number of subjects: 50
Study: 12698670

Group type: EXPERIMENTAL
Intervention: Plasma endothelin-1 levels
Number of subjects: 83
Study: 10740940

Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (6 hr)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No nicotine deprivation
Number of subjects: 56
Study: 8616947

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g, intravenous infusion, 60 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGE1 (40 microgram, intravenous infusion, 60 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (150 mL 0.9% saline, intravenous infusion, 60 minutes)
Number of subjects: 0
Study: 1412677

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 24
Study: 3907738

Group type: EXPERIMENTAL
Intervention: sobrerol 400 mg day-1 for 14 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 28248838

Group type: EXPERIMENTAL
Intervention: Family-Based Crisis Intervention (FBCI)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 142
Study: 29703266

Group type: EXPERIMENTAL
Intervention: Early and sustained prophylactic hypothermia to 33 °C for 72 hours
Number of subjects: 511

Group type: COMPARATOR
Intervention: Standard normothermia maintained at a core temperature of 37 °C
Number of subjects: 511
Study: 27217308

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program:10-14
Number of subjects: 14
Study: 25310007

Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Text-based intervention
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Control condition (general text-based advice)
Number of subjects: 2099
Study: 20673250

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 30
Study: 19184428

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (group A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No metoclopramide (group B)
Number of subjects: 95
Study: 18076258

Group type: EXPERIMENTAL
Intervention: Machine squat-jump at 21.6% of 1RM for peak power output
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Machine squat-jump at 39.0% of 1RM for mean power output
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Change in load around Pmax
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Standard deviations about means for peak and mean power
Number of subjects: 18
Study: 15367045

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Venlafaxine XR (225 mg/day)
Number of subjects: 195
Study: 11246060

Group type: EXPERIMENTAL
Intervention: Positive trial (ICARUS Israel carvedilol study, exercise study of candesartan cilexetil)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Negative or neutral trial (MACH‐1 trial of mibefradil, REACH trial of bosentan, CASCO trial of calcium sensitizer, ecadotril trial of neutral endopeptidase inhibitor)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Positive trial
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Negative or neutral trial
Number of subjects: 70
Study: 9768823

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7978587

Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.45 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 34
Study: 2637586

Group type: EXPERIMENTAL
Intervention: Birth Weight (BW) formula: 3 * BW (Kg) + 9 (cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total Body Length (TBL) formula: 1/3 TBL (cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Suprasternal Notch to Pubic Symphysis Length (SSL) formula: SSL (cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Shoulder to Umbilicus Length (SUL) formula: SUL (cm) + 2 (cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation coefficients (rs) between inserted length of UAC and each of the four parameters (BW, TBL, SSL, SUL)
Number of subjects: 120
Study: 4156290

Group type: EXPERIMENTAL
Intervention: Potassium clorazepate (15 mg. at night)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lorazepam (1 mg. t.d.s.)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Potassium clorazepate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 50
Study: 31725441

Group type: EXPERIMENTAL
Intervention: 4-hour simulation-based leadership training
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard orientation (control)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Leadership behaviors (mediated effect)
Number of subjects: 79
Study: 30785198

Group type: COMPARATOR
Intervention: GEMOX (gemcitabine 1000 mg/m2 on days 1 and 8, and oxaliplatin 100 mg/m2 on day 1)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine 1000 mg/m2, twice daily, on days 1‐14 and oxaliplatin 130 mg/m2 on day 1)
Number of subjects: 222

Group type: COMPARATOR
Intervention: GEMOX
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 222
Study: 29768118

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 343

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin)
Number of subjects: 343
Study: 27306520

Group type: COMPARATOR
Intervention: BBP (blackberry puree without ethanol)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BBP 12% (blackberry puree with 12% ethanol)
Number of subjects: 18
Study: 25236611

Group type: EXPERIMENTAL
Intervention: Multiple Traffic Light label
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Health Star Rating label
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Nutrition Information Panel (Control)
Number of subjects: 1500
Study: 21778912

Group type: COMPARATOR
Intervention: Walking (W)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Walking plus Resistance Training (WRT)
Number of subjects: 44
Study: 20356944

Group type: EXPERIMENTAL
Intervention: Annual invitation to mammography from age 40 or 41
Number of subjects: 53884
Study: 16938161

Group type: COMPARATOR
Intervention: Group G (General anaesthesia with propofol 2 mg kg‐1 and fentanyl 100 microg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group S (Spinal anaesthesia with propofol infusion at 2 mg kg‐1 h‐1 after a 0.2 mg kg‐1 bolus dose and fentanyl 100 microg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group T (TIVA with propofol 2 mg kg‐1 and fentanyl 100 microg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group S (Spinal anaesthesia)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group T (TIVA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study: 16249704

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Saquinavir AUC
Number of subjects: 258
Study: 11888453

Group type: EXPERIMENTAL
Intervention: Video-assisted surgery (VAS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional thyroid lobectomy (COS)
Number of subjects: 62
Study: 10761402

Group type: EXPERIMENTAL
Intervention: Brimonidine before and after ALT (B/B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brimonidine before and placebo after ALT (B/P)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Placebo before and brimonidine after ALT (P/B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo before and after ALT (P/P)
Number of subjects: 80
Study: 7723446

Group type: EXPERIMENTAL
Intervention: Mail-out/mail-back method
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Hand-out/assisted method
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: In-home interview method
Number of subjects: 697

Group type: COMPARATOR
Intervention: Mail-out/mail-back or hand-out/assisted method (nonresponders reassigned)
Number of subjects: 697
Study: 2035380

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 31
Study: 6271002

Group type: EXPERIMENTAL
Intervention: High cellulose diet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low cellulose diet
Number of subjects: 13
Study: 30997542

Group type: EXPERIMENTAL
Intervention: Chlorhexidine sponge dressings
Number of subjects: 18286

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel dressings
Number of subjects: 18286

Group type: COMPARATOR
Intervention: No chlorhexidine dressings
Number of subjects: 18286
Study: 28252827

Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises (Kegel exercises and pelvic movements) from 2 days postpartum until 3 months postpartum
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Direct Vagina Low Voltage Low Frequency Electric Stimulation (DES) 15 times (3 times a week for 30 min) starting at the sixth week postpartum combined with rehabilitation exercises
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group received routine postpartum guidance 2 hours postpartum
Number of subjects: 189
Study: 28247679

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus Miramistin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 150
Study: 24684985

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SD‐Ag)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SD‐Ag and mupirocin (combination)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SD‐Ag, mupirocin, and clotrimazole (combination)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SD‐Ag and mupirocin (combined effect)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SD‐Ag, mupirocin, and clotrimazole (combined effect)
Number of subjects: 18
Study: 23035004

Group type: EXPERIMENTAL
Intervention: Whole body vibration
Number of subjects: 30
Study: 21146205

Group type: EXPERIMENTAL
Intervention: VTD (Bortezomib with Thalidomide plus Dexamethasone)
Number of subjects: 480

Group type: COMPARATOR
Intervention: TD (Thalidomide plus Dexamethasone)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: VTD
Number of subjects: 480

Group type: COMPARATOR
Intervention: TD
Number of subjects: 480
Study: 17533081

Group type: EXPERIMENTAL
Intervention: Multidisciplinary literature-based approach to treatment
Number of subjects: 0
Study: 16322283

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy with Premarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic estrogen sulfate conjugates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen-dominated proliferative phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endometrial hyperplasia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grade 1 endometrioid adenocarcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grade 3 endometrioid carcinoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal endometrial epithelium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endometrioid tumors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor
Number of subjects: 0
Study: 12081832

Group type: EXPERIMENTAL
Intervention: Folate-rich diet (400 microg folate/d)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Folate supplement (400 microg/d)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Exclusion diet (placebo daily)
Number of subjects: 126
Study: 9459155

Group type: COMPARATOR
Intervention: Tamoxifen alone (40 mg per day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy (40 mg of tamoxifen + 75 microg of CV 205-502 + 3 x 0.2 mg of octreotide)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 22
Study: 7871564

Group type: EXPERIMENTAL
Intervention: 9 g of eicosapentanoic acid (EPA)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 18 g of eicosapentanoic acid (EPA)
Number of subjects: 133

Group type: COMPARATOR
Intervention: 9 g of corn oil (placebo)
Number of subjects: 133

Group type: COMPARATOR
Intervention: 18 g of corn oil (placebo)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: High dose fish oil (EPA)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Low dose fish oil (EPA)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: All groups (EPA and placebo)
Number of subjects: 133
Study: 2371432

Group type: EXPERIMENTAL
Intervention: Routine follow-up at 3 monthly intervals (follow-up group)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Annual follow-up (discharge group)
Number of subjects: 164
Study: 7362785

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: No anti-hypertensive treatment (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random sample from the same maternity hospital population
Number of subjects: 0
Study: 31786286

Group type: EXPERIMENTAL
Intervention: David procedure
Number of subjects: 523

Group type: COMPARATOR
Intervention: Bentall procedure
Number of subjects: 523
Study: 30071753

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) documentation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Age as a demographic variable
Number of subjects: 98
Study: 27984005

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 1000
Study: 25967270

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 148
Study: 23984100

Group type: EXPERIMENTAL
Intervention: 7.5% povidone iodine otic drops
Number of subjects: 34

Group type: COMPARATOR
Intervention: 1% Clotrimazole and lignocaine drops
Number of subjects: 34
Study: 17675766

Group type: EXPERIMENTAL
Intervention: Loxoprofen
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 14988571

Group type: COMPARATOR
Intervention: Aspirin therapy
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Anticoagulation (adjusted-dose warfarin)
Number of subjects: 834
Study: 10776870

Group type: EXPERIMENTAL
Intervention: Primary repair
Number of subjects: 176

Group type: COMPARATOR
Intervention: Diversion
Number of subjects: 176
Study: 8890138

Group type: EXPERIMENTAL
Intervention: Amoxicillin (first choice antibiotic for AOM)
Number of subjects: 0
Study: 1583904

Group type: EXPERIMENTAL
Intervention: Behavioral self-control training
Number of subjects: 140